Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedMay 20, 2026
DataAggregated Company Financials
Companies551
  • 7D-4.9%
  • 3M-7.2%
  • 1Y28.1%
  • YTD-1.1%

Over the last 7 days, the Biotech industry has dropped 4.9%, driven by a pullback from Regeneron Pharmaceuticals of 9.7%. Over the past 12 months, the industry was up 28%. As for the next few years, earnings are expected to grow by 25% per annum.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 21 May 2026US$1.3tUS$170.0b-US$12,747,149,302.5116x-98.2x7.4x
Sat, 18 Apr 2026US$1.3tUS$166.2b-US$11,948,698,496.8917.1x-111.2x8x
Mon, 16 Mar 2026US$1.3tUS$169.2b-US$15,183,509,438.6220.6x-85x7.6x
Wed, 11 Feb 2026US$1.3tUS$164.5b-US$14,762,511,997.9622x-87.9x7.9x
Fri, 09 Jan 2026US$1.3tUS$163.5b-US$15,084,223,249.5821.4x-83.4x7.7x
Sun, 07 Dec 2025US$1.2tUS$163.6b-US$16,089,277,339.7219.1x-76.7x7.5x
Tue, 04 Nov 2025US$1.1tUS$163.1b-US$16,314,684,162.7817x-69.6x7x
Thu, 02 Oct 2025US$1.1tUS$163.5b-US$18,248,451,852.6317.2x-60x6.7x
Sat, 30 Aug 2025US$1.1tUS$163.6b-US$18,635,211,382.3715.4x-56.7x6.5x
Mon, 28 Jul 2025US$992.7bUS$155.1b-US$22,919,892,186.1514.8x-43.3x6.4x
Wed, 25 Jun 2025US$932.9bUS$155.9b-US$23,877,765,865.0216.7x-39.1x6x
Fri, 23 May 2025US$907.8bUS$155.9b-US$24,354,722,512.9815.6x-37.3x5.8x
Sun, 20 Apr 2025US$756.8bUS$119.2b-US$36,619,881,205.0719.4x-20.7x6.3x
Tue, 18 Mar 2025US$839.1bUS$118.4b-US$37,618,768,555.5419.9x-22.3x7.1x
Thu, 13 Feb 2025US$815.2bUS$118.2b-US$35,533,913,315.5717x-22.9x6.9x
Sat, 11 Jan 2025US$967.2bUS$149.4b-US$26,283,970,082.7116.6x-36.8x6.5x
Mon, 09 Dec 2024US$1.0tUS$150.0b-US$26,481,489,967.0117.9x-39.1x6.9x
Wed, 06 Nov 2024US$1.1tUS$148.1b-US$30,555,050,448.5116.6x-34.9x7.2x
Fri, 04 Oct 2024US$891.6bUS$113.2b-US$35,958,059,033.0822x-24.8x7.9x
Sun, 01 Sep 2024US$909.4bUS$113.1b-US$35,712,101,098.3824x-25.5x8x
Tue, 30 Jul 2024US$1.2tUS$164.9b-US$28,963,503,229.8326.8x-43x7.5x
Thu, 27 Jun 2024US$1.2tUS$164.4b-US$27,986,453,486.3427.7x-41.4x7x
Sat, 25 May 2024US$1.1tUS$164.6b-US$26,747,196,206.4323.8x-42.1x6.8x
Mon, 22 Apr 2024US$1.1tUS$164.2b-US$23,311,155,066.5220.4x-45.9x6.5x
Wed, 20 Mar 2024US$1.2tUS$167.4b-US$21,814,367,317.9113.8x-53.5x7x
Fri, 16 Feb 2024US$1.2tUS$169.1b-US$20,723,712,339.7018.7x-55.6x6.8x
Sun, 14 Jan 2024US$1.4tUS$204.8b-US$22,497,556,941.0018.8x-63.9x7x
Tue, 12 Dec 2023US$1.3tUS$204.6b-US$22,091,146,901.0018.7x-58.6x6.3x
Thu, 09 Nov 2023US$1.2tUS$204.1b-US$20,943,935,957.0016.6x-59.3x6.1x
Sat, 07 Oct 2023US$1.3tUS$207.4b-US$13,060,168,797.0017.2x-96.3x6.1x
Mon, 04 Sep 2023US$1.3tUS$207.6b-US$12,421,503,459.0018.4x-104.2x6.2x
Wed, 02 Aug 2023US$1.1tUS$186.2b-US$14,964,083,330.0014.7x-76.4x6.1x
Fri, 30 Jun 2023US$1.1tUS$186.2b-US$16,044,205,476.0013.6x-69.4x6x
Sun, 28 May 2023US$1.1tUS$185.9b-US$16,045,698,796.0011.2x-69.9x6x
Price to Earnings Ratio

-69.9x


Total Market Cap: US$1.1tTotal Earnings: -US$16,045,698,796.00Total Revenue: US$185.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -57.6x202420252026
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.9x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 2.9% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.01%
Healthcare-0.23%
Biotech-4.95%
Biotech-4.95%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$212.301.8%
+US$6.7b		16.8%PE104.3x
ROIV Roivant SciencesUS$32.4110.9%
+US$2.3b		197.1%PS1742.7x
NTRA NateraUS$204.924.9%
+US$1.4b		35.6%PS11.7x
IMVT ImmunovantUS$35.5622.8%
+US$1.4b		144.2%PB8.5x
ALNY Alnylam PharmaceuticalsUS$298.482.4%
+US$934.6m		2.0%PE74.1x

Latest News

VCYT
US$45.19
Veracyte
7D
18.1%
1Y
63.7%
IMVT
US$35.56
Immunovant
7D
22.8%
1Y
144.2%
INSM
US$107.91
Insmed
7D
-8.5%
1Y
63.5%
ALNY
US$298.48
Alnylam Pharmaceuticals
7D
2.4%
1Y
2.0%
VRTX
US$430.44
Vertex Pharmaceuticals
7D
-5.0%
1Y
-1.1%
Narrative Update • May 19

VRTX: CF Franchise And Nephrology Pipeline Will Shape Balanced Future Risk Profile

Analysts have inched their fair value target for Vertex Pharmaceuticals higher to about $414 per share. This reflects updated assumptions that pair slightly more conservative revenue growth expectations with higher projected profit margins and a lower anticipated future P/E multiple.
ROIV
US$32.41
Roivant Sciences
7D
10.9%
1Y
197.1%
Narrative Update • May 19

ROIV: Settlement Windfall Will Shift Focus Toward 2026 Clinical Readouts

Analysts have increased their average price target on Roivant Sciences by about $0.04 to $35.71, citing updated models that factor in litigation settlement proceeds, the brepocitinib priority review and a lower assumed discount rate, along with adjusted profit margin and future P/E assumptions. Analyst Commentary Recent research updates on Roivant Sciences show a mix of optimism around litigation proceeds and key pipeline milestones, alongside some caution around how much of this is already reflected in current valuations.
GILD
US$130.69
Gilead Sciences
7D
-1.8%
1Y
21.3%
New Narrative • May 19

Attractive medium-term compounder with catalyst-rich profile, but with short-term volatility tied to investment phase

Below is a professional investment memo (buy‑side style, in English) on Gilead Sciences (GILD) based primarily on the 2025 Impact Report (pipeline + strategy + data extraction) and complemented with verified investor website + latest news analysis. Investment Memo – Gilead Sciences (NASDAQ: GILD) 1.
AMGN
US$331.57
Amgen
7D
-1.5%
1Y
22.2%
NTRA
US$204.92
Natera
7D
4.9%
1Y
35.6%
ABBV
US$212.30
AbbVie
7D
1.8%
1Y
16.8%
REGN
US$649.76
Regeneron Pharmaceuticals
7D
-9.7%
1Y
7.5%
Seeking Alpha • May 18

Regeneron: Time To Forget Fianlimab (Rating Upgrade)

Summary Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma. I see Regeneron as a strong buy after the pullback, as fianlimab-based combinations were not critical for long-term value creation. Return to stronger growth, expanding and maturing pipeline, and a strong balance sheet position the company well for success. Key risks include further Eylea franchise weakness and potential new clinical disappointments. Read the full article on Seeking Alpha
CELC
US$140.34
Celcuity
7D
12.8%
1Y
1,224.0%
SLS
US$8.97
SELLAS Life Sciences Group
7D
37.4%
1Y
427.6%
MRNA
US$48.12
Moderna
7D
-4.6%
1Y
86.5%
BIIB
US$187.80
Biogen
7D
-8.2%
1Y
48.1%
PCVX
US$47.17
Vaxcyte
7D
-13.1%
1Y
38.9%